Australian pharma accepts watchdog decision on doctor payments
Australia's competition watchdog has given drugmakers in the country two years to improve transparency relating to payments and sponsorship by drugmakers to individual healthcare professionals.
The Australian Competition and Consumer Commission (ACCC) has decided to authorise the research-based industry organisation Medicines Australia’s latest Code of Conduct for a period of two years - rather than five, as the group had sought.
Under the Code’s new edition (number 17), the organisation’s member companies will, for the first time, disclose aggregate payments which they make to doctors and consumer groups.
Announcing the decision, ACCC Commissioner Sarah Court said that "improving transparency around payments to individual doctors will play an important role in promoting community confidence in the integrity of these payments to healthcare professionals."